GO
Loading...

Enter multiple symbols separated by commas

Roche Holding AG

More

  • Regeneron drug tops rivals in some vision loss cases Wednesday, 18 Feb 2015 | 5:00 PM ET
    Eye examination

    Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.

  • Feb 5- Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira shares soared 35 percent to nearly $88 on Thursday, while Pfizer was up 2.7 percent at $32.93.

  • WASHINGTON, Jan 30- The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. Of that, $130 million would go to the NIH to fund the research cohort and $70 million to NIH's National Cancer...

  • European stocks end mixed, Greek banks tank Wednesday, 28 Jan 2015 | 11:34 AM ET

    European markets ended mixed on Wednesday after seesawing for much of the session, with indexes pressures by a staggering slump in Greek bank stocks.

  • NEW YORK, Jan 28- President Barack Obama's plan to put the United States at the forefront of individually tailored medical treatment should give a much-needed boost to research in the field but experts say it won't work without reforms to healthcare, including drug testing and insurance. Obama said he wanted the United States to "lead a new era of medicine, one...

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET
    Stock performance chart on computer screen

    Here are the fund managers Morningstar considers the best of the best.

  • Swiss large-caps lose $100B on currency move Thursday, 15 Jan 2015 | 8:45 AM ET

    The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...

  • *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-week decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • $1.8B drug deal to target cancer at genetic level Monday, 12 Jan 2015 | 8:05 AM ET

    Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."

  • US STOCKS-Futures climb after two-week drop Monday, 12 Jan 2015 | 7:35 AM ET

    *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Great day for Foundation Medicine: CEO   Monday, 12 Jan 2015 | 7:29 AM ET
    Great day for Foundation Medicine: CEO

    CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments. The drugmaker said it will tender for about 15.6 million Foundation shares at $50 a share, worth up to about $780...

  • Roche to buy majority stake in Foundation Medicine Monday, 12 Jan 2015 | 1:21 AM ET

    Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • 23 andMe, co-founded by Anne Wojcicki, the wife of Google co-founder Sergey Brin, will contribute the genome sequencing and data from its Parkinson's disease community. Genentech, a unit of Roche Holding AG, will work to identify potential therapeutics based on that information. There is no cure for Parkinson's, which affects about 1 million people in the United...